膜性肾病的诊断与靶抗原鉴定
膜性肾病是成人肾病综合征的常见病因,以肾小球基底膜上皮下免疫复合物沉积为特征。PLA2R占约60%的靶抗原,近7年发现NELL1、EXT1/EXT2等多种新抗原,具有特定疾病关联和临床病理特征。本文综述诊断方法并提出靶抗原检测算法。
要点
- PLA2R是膜性肾病最常见的靶抗原,约占60%的病例。
- 新发现的靶抗原包括NELL1、EXT1/EXT2、NCAM1、SEMA3B、PCDH7、FAT1、CNTN1、NTNG1、PCSK6和NDNF。
- 目前血清学检测仅可检测抗PLA2R和抗THSD7A抗体。
核心结论
- 膜性肾病不应笼统归为PLA2R阴性组,新发现的靶抗原具有特异性疾病关联、临床病理特征和治疗意义。
- 提出靶抗原检测的逻辑方法:包括血清学检测抗PLA2R和抗THSD7A抗体,以及肾活检检测靶抗原。
研究设计与样本
- 综述,回顾当前膜性肾病靶抗原检测方法并提诊断算法。
主要发现
- PLA2R是约60%膜性肾病病例的靶抗原。
- 新发现的靶抗原包括NELL1、EXT1/EXT2、NCAM1、SEMA3B、PCDH7、FAT1、CNTN1、NTNG1、PCSK6和NDNF,具有特定疾病关联、独特临床病理表现和治疗意义。
- 目前血清学检测仅可检测抗PLA2R和抗THSD7A抗体,新抗原的血清学检测尚未可用。
- 肾活检靶抗原检测可通过免疫组化或免疫荧光进行,或通过激光捕获显微切割联合质谱法。
临床怎么用
- 肾活检靶抗原检测可用免疫组化或免疫荧光;激光捕获显微切割联合质谱可一站式检测,尤其适用于罕见靶抗原。
- 目前新抗原的血清学抗体检测尚未可用,亟需开发不仅用于准确诊断、也指导治疗的血清学检测。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Membranous nephropathy (MN) is a common cause of nephrotic syndrome in adults. MN is characterized by subepithelial accumulation of immune complexes along the glomerular basement membrane. The immune complexes are composed of immunoglobulin G and a target antigen. PLA2R is the target antigen in approximately 60% of MN cases, and MN is traditionally classified as PLA2R-positive or PLA2R-negative MN. Over the last 7 years, additional target antigens have been identified, which have specific disease associations, distinctive clinical and pathologic findings, and therapeutic implications. The newly discovered target antigens include NELL1, EXT1/EXT2, NCAM1, SEMA3B, PCDH7, FAT1, CNTN1, NTNG1, PCSK6 and NDNF. To group all these antigens into a generic 'PLA2R-negative' MN group is imprecise and un-informative. We propose a logical approach for detection of the target antigen which includes (i) currently available serology-based testing to detect anti-PLA2R and anti-THSD7A antibodies; and (ii) kidney biopsy testing to detect the target antigens. Determination of the antigen on kidney biopsy can be done by immunohistochemistry or immunofluorescence studies. Alternatively, laser capture microdissection (LCM) of glomeruli followed by mass spectrometry (MS) can be used to identify a target antigen. LCM/MS has the advantage of being a one-stop test and is particularly useful for detection of rare target antigens. At the current time, while it is possible to detect the newer antigens by immunohistochemistry/immunofluorescence/LCM/MS, serology-based tests to detect serum antibodies to the new antigens are not yet available. It is critical that serology-based tests should be developed not just for accurate diagnosis, but as a guide for treatment. We review the current methodology and propose an algorithm for diagnosis and detection of target antigens in MN that may shape the current practice in the future. Membranous nephropathy (MN) results from accumulation of subepithelial immune complexes along the glomerular basement membrane.PLA2R is the most common target antigen, but newly discovered target antigens have filled the void of PLA2R-negative MN.MN associated with the newly discovered target antigens have distinctive clinical and pathologic findings, treatment and prognostic implications. These include NELL1, EXT1/EXT2, NCAM1, PCDH7, SEMA3B, CNTN1, FAT1, NDNF and PCSK6.Immunohistochemistry/immunofluorescence methodology is currently in use for detecting target antigens in kidney biopsy tissue, although we anticipate laser capture microdissection of glomeruli followed by mass spectrometry will become available soon.Serologic testing is currently available for only detecting antibodies to PLA2R and THSD7A. It is critical that serologic tests become available for detecting antibodies to the newly discovered antigens.
引用
- Sethi S, Fervenza FC. Membranous nephropathy-diagnosis and identification of target antigens. Nephrol Dial Transplant. 2024. PMID: 37863839. doi:10.1093/ndt/gfad227
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。